REVIEW   Open Access    

RXR signaling targeted cancer therapy

More Information
    1. Retinoic X receptors (RXRs) are important nuclear receptors mediating genetic transcriptions.

      Review the comprehensive role of RXR between RXR signaling and oncogenesis.

      Summarize the undervalued rexinoid-related cancer therapy.

      Discuss and propose its great potential in future clinics.

  • Retinoic X receptor (RXR) acts as a critical player in regulating a series of genetic transcriptions in cancer cells since it heterodimerizes with a third of nuclear receptors (NRs). However, RXR-targeted cancer therapy was greatly undervalued. Bexarotene (Targretin®) was the first synthetic rexinoid that was approved by Food and Drug Administration for refractory cutaneous T-cell lymphoma treatment in 2000. Afterward, researchers started to focus more on the function of RXR and modifications of RXR, such as phosphorylated-RXRα (p-RXRα) and truncated RXRα (tRXRα). Meanwhile, RXR-modulating drugs began to attract more interest from oncologists because of their potential in interfering with cancer cell proliferation, differentiation, and apoptosis according to the important and comprehensive regulation effects of RXR in tumorigenesis.
    Herein, we will review the comprehensive role of RXR between RXR signaling and oncogenesis, with a highlighted focus on the undervalued rexinoid-related cancer therapy, and discuss and propose its great potential in future clinics.
  • 加载中
  • [1] Siegel, R.L., Miller, K.D., Fuchs, H.E., and Jemal, A. (2022). Cancer statistics, 2022. CA Cancer J Clin 72, 7−33.

    View in Article CrossRef Google Scholar

    [2] Ni, X., Hu, G., and Cai, X. (2019). The success and the challenge of all-trans retinoic acid in the treatment of cancer. Crit Rev Food Sci Nutr 59, S71−S80.

    View in Article CrossRef Google Scholar

    [3] Gniadecki, R., Assaf, C., Bagot, M., et al. (2007). The optimal use of bexarotene in cutaneous T-cell lymphoma. Br J Dermatol 157, 433−440.

    View in Article CrossRef Google Scholar

    [4] de Almeida, N.R., and Conda-Sheridan, M. (2019). A review of the molecular design and biological activities of RXR agonists. Med Res Rev 39, 1372−1397.

    View in Article CrossRef Google Scholar

    [5] Altucci, L., Leibowitz, M.D., Ogilvie, K.M., et al. (2007). RAR and RXR modulation in cancer and metabolic disease. Nat Rev Drug Discov 6, 793−810.

    View in Article CrossRef Google Scholar

    [6] Evans, R.M., and Mangelsdorf, D.J. (2014). Nuclear Receptors, RXR, and the Big Bang. Cell 157, 255−266.

    View in Article CrossRef Google Scholar

    [7] Watanabe, M., and Kakuta, H. (2018). Retinoid X Receptor Antagonists. Int J Mol Sci 19.

    View in Article Google Scholar

    [8] Germain, P., Chambon, P., Eichele, G., et al. (2006). International Union of Pharmacology. LXIII. Retinoid X receptors. Pharmacol Rev 58, 760−772.

    View in Article Google Scholar

    [9] Mangelsdorf, D.J., Thummel, C., Beato, M., et al. (1995). The nuclear receptor superfamily: the second decade. Cell 83, 835−839.

    View in Article CrossRef Google Scholar

    [10] Tanaka, T., and De Luca, L.M. (2009). Therapeutic potential of "rexinoids" in cancer prevention and treatment. Cancer Res 69, 4945−4947.

    View in Article CrossRef Google Scholar

    [11] Chen, L., Wu, L., Zhu, L., and Zhao, Y. (2018). Overview of the structure-based non-genomic effects of the nuclear receptor RXRalpha. Cell Mol Biol Lett 23, 36.

    View in Article CrossRef Google Scholar

    [12] De Bosscher, K., Desmet, S.J., Clarisse, D., et al. (2020). Nuclear receptor crosstalk - defining the mechanisms for therapeutic innovation. Nat Rev Endocrinol 16, 363−377.

    View in Article CrossRef Google Scholar

    [13] Bushue, N., and Wan, Y.J. (2010). Retinoid pathway and cancer therapeutics. Adv Drug Deliv Rev 62, 1285−1298.

    View in Article CrossRef Google Scholar

    [14] di Masi, A., Leboffe, L., De Marinis, E., et al. (2015). Retinoic acid receptors: from molecular mechanisms to cancer therapy. Mol Aspects Med 41, 1−115.

    View in Article CrossRef Google Scholar

    [15] Song, S., Lippman, S.M., Zou, Y., et al. (2005). Induction of cyclooxygenase-2 by benzo[a]pyrene diol epoxide through inhibition of retinoic acid receptor-beta 2 expression. Oncogene 24, 8268−8276.

    View in Article CrossRef Google Scholar

    [16] Xu, X.C. (2007). Tumor-suppressive activity of retinoic acid receptor-beta in cancer. Cancer Lett 253, 14−24.

    View in Article CrossRef Google Scholar

    [17] Brown, G., and Petrie, K. (2021). The RARγ Oncogene: An Achilles Heel for Some Cancers. Int J Mol Sci 22.

    View in Article Google Scholar

    [18] Altucci, L., and Gronemeyer, H. (2001). The promise of retinoids to fight against cancer. Nat Rev Cancer 1, 181−193.

    View in Article CrossRef Google Scholar

    [19] Dahiya, R., Park, H.D., Cusick, J., et al. (1994). Inhibition of tumorigenic potential and prostate-specific antigen expression in LNCaP human prostate cancer cell line by 13-cis-retinoic acid. Int J Cancer 59, 126−132.

    View in Article CrossRef Google Scholar

    [20] Joseph, C., Al-Izzi, S., Alsaleem, M., et al. (2019). Retinoid X receptor gamma (RXRG) is an independent prognostic biomarker in ER-positive invasive breast cancer. Br J Cancer 121, 776−785.

    View in Article CrossRef Google Scholar

    [21] Zhu, J., Nasr, R., Pérès, L., et al. (2007). RXR is an essential component of the oncogenic PML/RARA complex in vivo. Cancer Cell 12, 23−35.

    View in Article CrossRef Google Scholar

    [22] Han, J., Won, M., Kim, J.H., et al. (2020). Cancer stem cell-targeted bio-imaging and chemotherapeutic perspective. Chem Soc Rev 49, 7856−7878.

    View in Article CrossRef Google Scholar

    [23] Chaffer, C.L., and Weinberg, R.A. (2011). A perspective on cancer cell metastasis. Science 331, 1559−1564.

    View in Article CrossRef Google Scholar

    [24] Lawson, D.A., Bhakta, N.R., Kessenbrock, K., et al. (2015). Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells. Nature 526, 131−135.

    View in Article CrossRef Google Scholar

    [25] Steinbichler, T.B., Dudás, J., Skvortsov, S., et al. (2018). Therapy resistance mediated by cancer stem cells. Semin Cancer Biol 53, 156−167.

    View in Article CrossRef Google Scholar

    [26] Zheng, H., Pomyen, Y., Hernandez, M.O., et al. (2018). Single-cell analysis reveals cancer stem cell heterogeneity in hepatocellular carcinoma. Hepatology 68, 127−140.

    View in Article CrossRef Google Scholar

    [27] Ahmed, N., Escalona, R., Leung, D., et al. (2018). Tumour microenvironment and metabolic plasticity in cancer and cancer stem cells: Perspectives on metabolic and immune regulatory signatures in chemoresistant ovarian cancer stem cells. Semin Cancer Biol 53, 265−281.

    View in Article CrossRef Google Scholar

    [28] Chen, J., Cao, X., An, Q., et al. (2018). Inhibition of cancer stem cell like cells by a synthetic retinoid. Nat Commun 9, 1406.

    View in Article CrossRef Google Scholar

    [29] Qi, F., Qin, W., Zhang, Y., et al. (2021). Sulfarotene, a synthetic retinoid, overcomes stemness and sorafenib resistance of hepatocellular carcinoma via suppressing SOS2-RAS pathway. J Exp Clin Cancer Res 40, 280.

    View in Article CrossRef Google Scholar

    [30] Brown, G. (2023). Targeting the Retinoic Acid Pathway to Eradicate Cancer Stem Cells. Int J Mol Sci 24.

    View in Article Google Scholar

    [31] Zhang, R., Li, H., Zhang, S., et al. (2018). RXRα provokes tumor suppression through p53/p21/p16 and PI3K-AKT signaling pathways during stem cell differentiation and in cancer cells. Cell Death Dis 9, 532.

    View in Article CrossRef Google Scholar

    [32] Williams, A.P., Garner, E.F., Stafman, L.L., et al. (2019). UAB30, A Novel Rexinoid Agonist, Decreases Stemness In Group 3 Medulloblastoma Human Cell Line Xenografts. Transl Oncol 12, 1364−1374.

    View in Article CrossRef Google Scholar

    [33] Moerland, J.A., Zhang, D., Reich, L.A., et al. (2020). The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer. Sci Rep 10, 22244.

    View in Article CrossRef Google Scholar

    [34] Gonzalez, H., Hagerling, C., and Werb, Z. (2018). Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev 32, 1267−1284.

    View in Article CrossRef Google Scholar

    [35] Lin, H.H., Peng, Y.J., Tsai, M.J., et al. (2020). Upregulation of amphiregulin by retinoic acid and Wnt signalling promotes liver cancer cell proliferation. J Cell Physiol 235, 1689−1699.

    View in Article CrossRef Google Scholar

    [36] Viragova, S., Aparicio, L., Palmerini, P., et al. (2023). Inverse agonists of RAR/RXR signaling as lineage-specific anti-tumor agents against human Adenoid Cystic Carcinoma. J Natl Cancer Inst 10.1093/jnci/djad062.

    View in Article Google Scholar

    [37] Xie, G., Zhou, Y., Tu, X., et al. (2020). Centrosomal Localization of RXRalpha Promotes PLK1 Activation and Mitotic Progression and Constitutes a Tumor Vulnerability. Dev Cell 55, 707-722 e709.

    View in Article Google Scholar

    [38] Singh, P., Pesenti, M.E., Maffini, S., et al. (2021). BUB1 and CENP-U, Primed by CDK1, Are the Main PLK1 Kinetochore Receptors in Mitosis. Mol Cell 81, 67-87 e69.

    View in Article Google Scholar

    [39] Xu, J., Shen, C., Wang, T., and Quan, J. (2013). Structural basis for the inhibition of Polo-like kinase 1. Nat Struct Mol Biol 20, 1047−1053.

    View in Article CrossRef Google Scholar

    [40] Joukov, V., Walter, J.C., and De Nicolo, A. (2014). The Cep192-organized aurora A-Plk1 cascade is essential for centrosome cycle and bipolar spindle assembly. Mol Cell 55, 578−591.

    View in Article CrossRef Google Scholar

    [41] Deng, D., and Shah, K. (2020). TRAIL of Hope Meeting Resistance in Cancer. Trends Cancer 6, 989−1001.

    View in Article CrossRef Google Scholar

    [42] Chen, L., Aleshin, A.E., Alitongbieke, G., et al. (2017). Modulation of nongenomic activation of PI3K signalling by tetramerization of N-terminally-cleaved RXRalpha. Nat Commun 8, 16066.

    View in Article CrossRef Google Scholar

    [43] Plevin, M.J., Mills, M.M., and Ikura, M. (2005). The LxxLL motif: a multifunctional binding sequence in transcriptional regulation. Trends Biochem Sci 30, 66−69.

    View in Article CrossRef Google Scholar

    [44] Zhou, H., Liu, W., Su, Y., et al. (2010). NSAID sulindac and its analog bind RXRalpha and inhibit RXRalpha-dependent AKT signaling. Cancer Cell 17, 560−573.

    View in Article CrossRef Google Scholar

    [45] Ye, X., Wu, H., Sheng, L., et al. (2019). Oncogenic potential of truncated RXRα during colitis-associated colorectal tumorigenesis by promoting IL-6-STAT3 signaling. Nat Commun 10, 1463.

    View in Article CrossRef Google Scholar

    [46] Chen, Z.J. (2012). Ubiquitination in signaling to and activation of IKK. Immunol Rev 246, 95−106.

    View in Article CrossRef Google Scholar

    [47] Grivennikov, S., Karin, E., Terzic, J., et al. (2009). IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15, 103−113.

    View in Article CrossRef Google Scholar

    [48] Zhu, M., Li, S., Cao, X., et al. (2022). The STAT family: key transcription factors mediating crosstalk between cancer stem cells and tumor immune microenvironment. Semin Cancer Biol 10.1016/j.semcancer.2022.11.011.

    View in Article Google Scholar

    [49] Crowe, D.L., and Chandraratna, R.A. (2004). A retinoid X receptor (RXR)-selective retinoid reveals that RXR-alpha is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor ligands. Breast Cancer Res 6, R546−555.

    View in Article CrossRef Google Scholar

    [50] Yamazaki, K., Shimizu, M., Okuno, M., et al. (2007). Synergistic effects of RXR alpha and PPAR gamma ligands to inhibit growth in human colon cancer cells-phosphorylated RXR alpha is a critical target for colon cancer management. Gut 56, 1557−1563.

    View in Article CrossRef Google Scholar

    [51] Peng, Y., Wang, Y., Tang, N., et al. (2018). Andrographolide inhibits breast cancer through suppressing COX-2 expression and angiogenesis via inactivation of p300 signaling and VEGF pathway. J Exp Clin Cancer Res 37, 248.

    View in Article CrossRef Google Scholar

    [52] Wang, W., Zhao, M., Cui, L., et al. (2020). Characterization of a novel HDAC/RXR/HtrA1 signaling axis as a novel target to overcome cisplatin resistance in human non-small cell lung cancer. Mol Cancer 19, 134.

    View in Article CrossRef Google Scholar

    [53] Xu, Y., Jiang, Z., Zhang, Z., et al. (2014). HtrA1 downregulation induces cisplatin resistance in lung adenocarcinoma by promoting cancer stem cell-like properties. J Cell Biochem 115, 1112−1121.

    View in Article CrossRef Google Scholar

    [54] Wang, P., Wang, Z., and Liu, J. (2020). Role of HDACs in normal and malignant hematopoiesis. Mol Cancer 19, 5.

    View in Article CrossRef Google Scholar

    [55] Yamauchi, T., Waki, H., Kamon, J., et al. (2001). Inhibition of RXR and PPARgamma ameliorates diet-induced obesity and type 2 diabetes. J Clin Invest 108, 1001−1013.

    View in Article CrossRef Google Scholar

    [56] Marin-Bejar, O., Rogiers, A., Dewaele, M., et al. (2021). Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma. Cancer Cell 39, 1135−1149.e1138.

    View in Article CrossRef Google Scholar

    [57] Rambow, F., Rogiers, A., Marin-Bejar, O., et al. (2018). Toward Minimal Residual Disease-Directed Therapy in Melanoma. Cell 174, 843-855 e819.

    View in Article Google Scholar

    [58] Viola, A., Munari, F., Sánchez-Rodríguez, R., et al. (2019). The Metabolic Signature of Macrophage Responses. Front Immunol 10, 1462.

    View in Article CrossRef Google Scholar

    [59] Babaev, V.R., Yancey, P.G., Ryzhov, S.V., et al. (2005). Conditional knockout of macrophage PPARgamma increases atherosclerosis in C57BL/6 and low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 25, 1647−1653.

    View in Article CrossRef Google Scholar

    [60] Oyarce, C., Vizcaino-Castro, A., Chen, S., et al. (2021). Re-polarization of immunosuppressive macrophages to tumor-cytotoxic macrophages by repurposed metabolic drugs. Oncoimmunology 10, 1898753.

    View in Article CrossRef Google Scholar

    [61] Wang, Q., Tu, X., Wang, X., et al. (2022). Design, synthesis and biological evaluation of acyl hydrazones-based derivatives as RXRα-targeted anti-mitotic agents. Bioorg Chem 128, 106069.

    View in Article CrossRef Google Scholar

    [62] le Maire, A., Teyssier, C., Balaguer, P., et al. (2019). Regulation of RXR-RAR Heterodimers by RXR- and RAR-Specific Ligands and Their Combinations. Cells 8.

    View in Article Google Scholar

    [63] Wang, G.H., Jiang, F.Q., Duan, Y.H., et al. (2013). Targeting truncated retinoid X receptor-α by CF31 induces TNF-α-dependent apoptosis. Cancer Res 73, 307−318.

    View in Article Google Scholar

    [64] Wilson, A.J., Liu, A.Y., Roland, J., et al. (2013). TR3 modulates platinum resistance in ovarian cancer. Cancer Res 73, 4758−4769.

    View in Article CrossRef Google Scholar

    [65] Tran, T.T., and Lee, K. (2022). TR3 Enhances AR Variant Production and Transactivation, Promoting Androgen Independence of Prostate Cancer Cells. Cancers (Basel) 14.

    View in Article Google Scholar

    [66] Chen, F., Chen, J., Lin, J., et al. (2015). NSC-640358 acts as RXRα ligand to promote TNFα-mediated apoptosis of cancer cell. Protein Cell 6, 654−666.

    View in Article CrossRef Google Scholar

    [67] Noel, P., Von Hoff, D.D., Saluja, A.K., et al. (2019). Triptolide and Its Derivatives as Cancer Therapies. Trends Pharmacol Sci 40, 327−341.

    View in Article CrossRef Google Scholar

    [68] Wang, P.Y., Zeng, W.J., Liu, J., et al. (2017). TRC4, an improved triptolide derivative, specifically targets to truncated form of retinoid X receptor-alpha in cancer cells. Biochem Pharmacol 124, 19−28.

    View in Article CrossRef Google Scholar

    [69] Zhu, X., Li, J., Ning, H., et al. (2021). α-Mangostin Induces Apoptosis and Inhibits Metastasis of Breast Cancer Cells via Regulating RXRα-AKT Signaling Pathway. Front Pharmacol 12, 739658.

    View in Article CrossRef Google Scholar

    [70] Kolluri, S.K., Corr, M., James, S.Y., et al. (2005). The R-enantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis. Proc Natl Acad Sci U S A 102, 2525−2530.

    View in Article CrossRef Google Scholar

    [71] Lala, D.S., Mukherjee, R., Schulman, I.G., et al. (1996). Activation of specific RXR heterodimers by an antagonist of RXR homodimers. Nature 383, 450−453.

    View in Article CrossRef Google Scholar

    [72] Hedvat, M., Jain, A., Carson, D.A., et al. (2004). Inhibition of HER-kinase activation prevents ERK-mediated degradation of PPARgamma. Cancer Cell 5, 565−574.

    View in Article CrossRef Google Scholar

    [73] Miller, A.L., Garcia, P.L., Fehling, S.C., et al. (2021). The BET Inhibitor JQ1 Augments the Antitumor Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer. Cancers (Basel) 13.

    View in Article Google Scholar

    [74] Calkin, A.C., and Tontonoz, P. (2012). Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR. Nat Rev Mol Cell Biol 13, 213−224.

    View in Article CrossRef Google Scholar

    [75] Lo Sasso, G., Bovenga, F., Murzilli, S., et al. (2013). Liver X receptors inhibit proliferation of human colorectal cancer cells and growth of intestinal tumors in mice. Gastroenterology 144, 1497-1507, 1507.e1491-1413.

    View in Article Google Scholar

    [76] Wan, W., Hou, Y., Wang, K., et al. (2019). The LXR-623-induced long non-coding RNA LINC01125 suppresses the proliferation of breast cancer cells via PTEN/AKT/p53 signaling pathway. Cell Death Dis 10, 248.

    View in Article CrossRef Google Scholar

    [77] Pencheva, N., Buss, C.G., Posada, J., et al. (2014). Broad-spectrum therapeutic suppression of metastatic melanoma through nuclear hormone receptor activation. Cell 156, 986-1001, 10.1016/j.cell.2014.01.038.

    View in Article Google Scholar

    [78] Hutchinson, S.A., Websdale, A., Cioccoloni, G., et al. (2021). Liver x receptor alpha drives chemoresistance in response to side-chain hydroxycholesterols in triple negative breast cancer. Oncogene 40, 2872−2883.

    View in Article CrossRef Google Scholar

    [79] Shimizu, M., Takai, K., and Moriwaki, H. (2009). Strategy and mechanism for the prevention of hepatocellular carcinoma: phosphorylated retinoid X receptor alpha is a critical target for hepatocellular carcinoma chemoprevention. Cancer Sci 100, 369−374.

    View in Article CrossRef Google Scholar

    [80] Chandra, V., Huang, P., Hamuro, Y., et al. (2008). Structure of the intact PPAR-gamma-RXR- nuclear receptor complex on DNA. Nature 456, 350−356.

    View in Article CrossRef Google Scholar

  • Cite this article:

    Zhao W., Li S., Chen R., et al., (2023). RXR signaling targeted cancer therapy. The Innovation Life 1(1), 100014. https://doi.org/10.59717/j.xinn-life.2023.100014
    Zhao W., Li S., Chen R., et al., (2023). RXR signaling targeted cancer therapy. The Innovation Life 1(1), 100014. https://doi.org/10.59717/j.xinn-life.2023.100014

Figures(8)     Tables(1)

Share

  • Share the QR code with wechat scanning code to friends and circle of friends.

Article Metrics

Article views(3364) PDF downloads(313) Cited by(0)

Relative Articles

Article Contents

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint